Advertisement

Archives of Virology

, Volume 160, Issue 5, pp 1153–1161 | Cite as

Novel rat models to study primary genital herpes simplex virus-2 infection

  • Karin Önnheim
  • Maria Ekblad
  • Staffan Görander
  • Stefan Lange
  • Eva Jennische
  • Tomas Bergström
  • Sheryl Wildt
  • Jan-Åke LiljeqvistEmail author
Original Article

Abstract

In this study we describe that six rat models (SD, WIST, LEW, BN, F344 and DA) are susceptible to intravaginal herpes simplex virus-2 (HSV-2) infection after pre-treatment with progesterone. At a virus dose of 5 × 106 PFU of HSV-2, all rat models were infected presenting anti-HSV-2 antibodies, infectious virus in vaginal washes, and HSV-2 DNA genome copies in lumbosacral dorsal root ganglia and the spinal cord. Most of the LEW, BN, F344, and DA rats succumbed in systemic progressive symptoms at day 8-14 post infection, but presented no or mild genital inflammation while SD and WIST rats were mostly infected asymptomatically. Infected SD rats did not reactivate HSV-2 spontaneously or after cortisone treatment. In an HSV-2 virus dose reduction study, F344 rats were shown to be most susceptible. We also investigated whether an attenuated HSV-1 strain (KOS321) given intravaginally, could protect from a subsequent HSV-2 infection. All LEW, BN, and F344 rats survived a primary HSV-1 infection and no neuronal infection was established. In BN and F344 rats, anti-HSV-1 antibodies were readily detected while LEW rats were seronegative. In contrast to naïve LEW, BN, and F344 rats where only 3 of 18 animals survived 5 × 106 PFU of HSV-2, 23 of 25 previously HSV-1 infected rats survived a challenge with HSV-2. The described models provide a new approach to investigate protective effects of anti-viral microbicides and vaccine candidates, as well as to study asymptomatic primary genital HSV-2 infection.

Keywords

Post Infection Sprague Dawley Dark Agouti Progesterone Treatment Genital Mucosa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This work was supported by grants from the ALF Foundation at Sahlgrenska University Hospital, the Gothenburg Medical Society (GLS), the Adlerbertska Foundation, the Clas Groschinsky Foundation, the Medical Research Council and Torsten Söderbergs Foundation. We thank Carolina Gustafsson for technical assistance.

Conflict of interest

None declared.

Ethical standard

This study was carried out in accordance to the rules stated by the Swedish board of agriculture. All animal experiments were approved by the ethical board in Gothenburg (Dnr 171-2013).

References

  1. 1.
    Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE (1999) A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 341(19):1432–1438CrossRefPubMedGoogle Scholar
  2. 2.
    Schiffer JT, Corey L (2013) Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 19(3):280–290CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Looker KJ, Garnett GP (2005) A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 81(2):103–107CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 20(1):73–83CrossRefPubMedGoogle Scholar
  5. 5.
    Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT et al (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366(1):34–43CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr et al (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4):331–340CrossRefPubMedGoogle Scholar
  7. 7.
    Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70(3):369–380PubMedGoogle Scholar
  8. 8.
    Stanberry LR (1995) Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol 3(6):244–247CrossRefPubMedGoogle Scholar
  9. 9.
    Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, Distefano DJ et al (2014) Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J Virol 88(4):2000–2010CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE et al (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200(7):1088–1095CrossRefPubMedGoogle Scholar
  11. 11.
    Bergström T, Svennerhom B, Conradi N, Horal P, Vahlne A (1991) Discrimination of herpes simplex virus types 1 and 2 cerebral infections in a rat model. Acta Neuropath. 82:395–401CrossRefPubMedGoogle Scholar
  12. 12.
    Beers DR, Henkel JS, Schaefer DC, Rose JW, Stroop WG (1993) Neuropathology of herpes simplex virus encephalitis in a rat seizure model. J Neuropathol Exp Neurol 52(3):241–252CrossRefPubMedGoogle Scholar
  13. 13.
    Bereczky-Veress B, Lidman O, Sabri F, Bednar I, Granath F, Bergstrom T et al (2008) Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis. J Neurovirol 14(2):102–118CrossRefPubMedGoogle Scholar
  14. 14.
    Wang H, Davido DJ, Morrison LA (2013) HSV-1 strain McKrae is more neuroinvasive than HSV-1 KOS after corneal or vaginal inoculation in mice. Virus Res 173(2):436–440CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Gorander S, Harandi AM, Lindqvist M, Bergstrom T, Liljeqvist JA (2012) Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease. J Virol 86(14):7544–7553CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Jeansson S, Forsgren M, Svennerholm B (1983) Evaluation of solubilized herpes simplex virus membrane antigen by enzyme-linked immunosorbent assay. J Clin Microbiol 18(5):1160–1166PubMedCentralPubMedGoogle Scholar
  17. 17.
    Liljeqvist J-Å, Trybala E, Svennerholm B, Jeansson S, Sjögren-Jansson E, Bergström T (1998) Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies. J Gen Virol 79:1215–1224PubMedGoogle Scholar
  18. 18.
    Namvar L, Olofsson S, Bergstrom T, Lindh M (2005) Detection and typing of Herpes Simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2. J Clin Microbiol 43(5):2058–2064CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Westwood FR (2008) The female rat reproductive cycle: a practical histological guide to staging. Toxicol Pathol 36(3):375–384CrossRefPubMedGoogle Scholar
  20. 20.
    Svensson A, Kaim J, Mallard C, Olsson A, Brodin E, Hokfelt T et al (2005) Neurokinin 1 receptor signaling affects the local innate immune defense against genital herpes virus infection. J Immunol 175(10):6802–6811CrossRefPubMedGoogle Scholar
  21. 21.
    Parr MB, Parr EL (2003) Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites. J Neurovirol 9(6):594–602CrossRefPubMedGoogle Scholar
  22. 22.
    Ohashi M, Bertke AS, Patel A, Krause PR (2011) Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia. J Virol 85(6):3030–3032CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Fleck M, Podlech J, Weise K, Muntefering H, Falke D (1993) Pathogenesis of HSV-1/2 induced vaginitis/vulvitis of the mouse: dependence of lesions on genetic properties of the virus and analysis of pathohistology. Arch Virol 129(1–4):35–51CrossRefPubMedGoogle Scholar
  24. 24.
    Podlech J, Hengerer F, Fleck M, Eray K, Falke D (1996) Asymptomatic vaginal herpes simplex virus infections in mice: virology and pathohistology. Arch Virol 141(2):263–274CrossRefPubMedGoogle Scholar
  25. 25.
    Ljungdahl A, Kristensson K, Lundberg JM, Lycke E, Svennerholm B, Ziegler R (1986) Herpes simplex virus infection in capsaicin-treated mice. J Neurol Sci 72(2–3):223–230CrossRefPubMedGoogle Scholar
  26. 26.
    Stanberry LR (1990) Capsaicin interferes with the centrifugal spread of virus in primary and recurrent genital herpes simplex virus infections. J Infect Dis 162(1):29–34CrossRefPubMedGoogle Scholar
  27. 27.
    Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC Jr (1982) Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 146(3):397–404CrossRefPubMedGoogle Scholar
  28. 28.
    Simmons A, Nash AA (1984) Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J Virol 52(3):816–821PubMedCentralPubMedGoogle Scholar
  29. 29.
    Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK et al (1997) Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 337(16):1105–1111CrossRefPubMedGoogle Scholar
  30. 30.
    Bernstein DI, Bellamy AR, Hook EW 3rd, Levin MJ, Wald A, Ewell MG et al (2013) Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 56(3):344–351CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    McDermott MR, Smiley JR, Leslie P, Brais J, Rudzroga HE, Bienenstock J (1984) Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 51(3):747–753PubMedCentralPubMedGoogle Scholar
  32. 32.
    Stanberry LR, Kit S, Myers MG (1985) Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J Virol 55(2):322–328PubMedCentralPubMedGoogle Scholar
  33. 33.
    Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, Wald A et al (2010) Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 184(6):3250–3259CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Posavad CM, Wald A, Hosken N, Huang ML, Koelle DM, Ashley RL et al (2003) T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J Immunol 170(8):4380–4388CrossRefPubMedGoogle Scholar
  35. 35.
    Fahey JR, Katoh H, Malcolm R, Perez AV (2013) The case for genetic monitoring of mice and rats used in biomedical research. Mamm Genome 24(3–4):89–94CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  • Karin Önnheim
    • 1
  • Maria Ekblad
    • 1
  • Staffan Görander
    • 1
  • Stefan Lange
    • 2
  • Eva Jennische
    • 3
  • Tomas Bergström
    • 1
  • Sheryl Wildt
    • 4
  • Jan-Åke Liljeqvist
    • 1
    Email author
  1. 1.Section of Virology, Department of Infectious Medicine, Institute of BiomedicineSahlgrenska Academy at University of GothenburgGothenburgSweden
  2. 2.Section of Bacteriology, Department of Infectious Medicine, Institute of BiomedicineSahlgrenska Academy at University of GothenburgGothenburgSweden
  3. 3.Department of Medical Biochemistry and Cell Biology, Institute of BiomedicineSahlgrenska Academy at University of GothenburgGothenburgSweden
  4. 4.Harlan LaboratoriesIndianapolisUSA

Personalised recommendations